News
Idarucizumab reverses dabigatran’s anticoagulant effects
Key clinical point: The investigational monoclonal antibody idarucizumab reversed the anticoagulant effects of dabigatran. Major finding:...
News
FDA approves cangrelor, an intravenous antiplatelet drug
News
Physician suicide needs attention
News
To FDA: Wait for clinical outcomes data
Article
New and Noteworthy Information—July 2015
News
Ego depletion in the clinic
News
Drug reverses anticoagulant effect of dabigatran
dabigatran in real-world situations. In the RE-VERSE AD trial, idarucizumab normalized diluted thrombin time (dTT) and ecarin clotting time (ECT...
News
Thiotepa, rituximab improve response in CNS lymphoma
site of 13-ICML LUGANO—Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety...
News
Bridge therapy not necessary in AFib, team says
TORONTO—Bridge anticoagulant therapy appears to be unnecessary in patients with atrial fibrillation (AFib) undergoing elective surgery, according...
News
FDA grants vaccine orphan designation for MM
The US Food and Drug Administration (FDA) has granted a novel vaccine orphan designation as a treatment for multiple myeloma (MM). The vaccine,...